Biomedical engineers at Duke University have pioneered a platform that merges automated wet lab protocols with sophisticated artificial intelligence to revolutionize nanoparticle design for drug delivery. This system accelerates optimization of carrier properties for difficult-to-encapsulate therapeutics, enhancing delivery efficiency and precision. Partnering with Lila Sciences’ funding round, these technological leaps promise to substantially speed early-stage drug development, optimizing nanoparticle formulations for clinical application.